Investor Presentaiton
sanofi
Positive phase 1/2 results support SP0256 as the backbone for
the combo respiratory vaccine
% participants with
solicited reactions D7
100
80
60
60
40
20
20
Reactogenicity
(selected formulation)
Neut Ab GMTR (D29/D1)*
25
Boosted RSV-A Neutralizing
Antibodies (selected formulation)
25
20
20
15
10
11.5
5
5.4
I
1.0
-
MRNA RSV OA vaccine
was well tolerated
mRNA RSV OA vaccine
significantly boosted RSV
neutralizing antibody
responses
Vaccine
Younger
Vaccine
Older
Saline
Older
Adults 18-49
Adults >60
Adults >60
Grade 1
Grade 2
Grade 3
*RSV-A neutralizing antibodies Geometric Mean Titer ratio (D29 vs baseline D1
38 Vaccines Investor Event
0
Vaccine
Younger
Vaccine
Older
Saline
Older
Adults 18-49
Adults >60
Adults >60View entire presentation